Nemolizumab for LS

Inclusion Criteria: * Ability to comprehend and willingness to sign a written * Females only ≥18 years of age at time of screening * Documentation of biopsy-proven anogenital LS. * Baseline itch NRS score ≥ 6 in anogenital area. * Prior use of topical corticosteroid. * Participants who agree to discontinue all agents used by the participant to treat LS from the screening visit through the final safety follow-up visit, aside from rescue therapy as specified in "Concomitant therapy" in the protocol Exclusion Criteria: * Participants who do not have LS involving anogenital area. * Need for receiving a live vaccine right before or during treatment with the study drug. * Planned or expected major surgical procedure during the clinical study. * Pregnant or lactating participants or those considering pregnancy during the period of their study participation. * Participants unwilling to refrain from using prohibited medications during the clinical study. * Patients who have been treated with systemic medications for other dermatologic conditions or itch within the past 4 months. * Patients that undergone had physical treatment modalities, such as CO2 laser or radiofrequency microneedling to the anogenital region. * Body weight \<30 kg. * Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the baseline visit with another investigational medication or current enrollment in another investigational drug protocol. * Previous treatment with nemolizu…